Evidence map›Paper›PMID 40504226›Full record

ArticleOxford review of economic policy2020

A cost-benefit analysis of the COVID-19 disease.

Robert Rowthorn, Jan Maciejowski

Abstract read
In one paragraph

Article in Oxford review of economic policy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.

0numbers the graph read from it
0cells of the map it votes in
38citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

38 citing papers in PubMed.

  1. Optimizing infectious disease mitigation under dynamic conditions.Proceedings of the National Academy of Sciences of the United States of America · 2026
    Article
  2. Article
  3. Article
  4. Path integral control of a stochastic multi-risk SIR pandemic model.Theory in biosciences = Theorie in den Biowissenschaften · 2023
    Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Preferences for COVID-19 epidemic control measures among French adults: a discrete choice experiment.The European journal of health economics : HEPAC : health economics in prevention and care · 2023
    Article
  10. Article
  11. Article
  12. Article
  13. The economics of stop-and-go epidemic control.Socio-economic planning sciences · 2022
    Article
  14. Article
  15. Article
  16. Article
  17. A "Ballpark" Assessment of Social Distancing Efficiency in the Early Stages of the COVID-19 Pandemic.International journal of environmental research and public health · 2022
    Article
  18. The anxiety of not knowing: Diagnosis uncertainty about COVID-19.Current psychology (New Brunswick, N.J.) · 2022
    Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Robert RowthornEmeritus Professor of Economics, University of Cambridge.
Jan MaciejowskiEmeritus Professor of Control Engineering, University of Cambridge.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The British government has been debating how to escape from the lockdown without provoking a resurgence of the COVID-19 disease. There is a growing recognition of the damage the lockdown has caused to economic and social life. This paper presents a simple cost-benefit analysis inspired by optimal control theory and incorporating the SIR model of disease propagation. It also reports simulations informed by the theoretical discussion. The optimal path for government intervention is computed under a variety of conditions. These include a cap on the permitted level of infection to avoid overload of the health system, and the introduction of a test and trace system. We quantify the benefits of early intervention to control the disease. We also examine how the government's valuation of life influences the optimal path. A 10-week lockdown is only optimal if the value of life for COVID-19 victims exceeds £10m. The study is based on a standard but simple epidemiological model, and should therefore be regarded as presenting a methodological framework rather than giving policy prescriptions.

Indexed as

benefit–costCOVID-19lockdown

Identifiers

PMID40504226
PMCPMC7499782

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.